FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327701904> ?p ?o ?g. }

• W4327701904 endingPage "885" @default.
• W4327701904 startingPage "872" @default.
• W4327701904 abstract "Abstract STUDY QUESTION Can recurrent embryo developmental problems after ICSI be overcome by assisted oocyte activation (AOA)? SUMMARY ANSWER AOA did not improve blastocyst formation in our patient cohort with recurrent embryo developmental problems after ICSI. WHAT IS KNOWN ALREADY The use of AOA to artificially induce calcium (Ca2+) rises by using Ca2+ ionophores (mainly calcimycin and ionomycin) has been reported as very effective in overcoming fertilization failure after ICSI, especially in patients whose Ca2+ dynamics during fertilization are deficient. However, there is only scarce and contradictory literature on the use of AOA to overcome embryo developmental problems after ICSI, and it is not clear whether abnormal Ca2+ patterns during fertilization disturb human preimplantation embryo development. Moreover, poor embryo development after ICSI has also been linked to genetic defects in the subcortical maternal complex (SCMC) genes. STUDY DESIGN, SIZE, DURATION This prospective cohort single-center study compared ICSI-AOA cycles and previous ICSI cycles in couples with normal fertilization rates (≥60%) but impaired embryonic development (≤15% blastocyst formation) in at least two previous ICSI cycles. In total, 42 couples with embryo developmental problems were included in this study from January 2018 to January 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS Of the 42 couples included, 17 underwent an ICSI-AOA cycle consisting of CaCl2 injection and double ionomycin exposure. Fertilization, blastocyst development, pregnancy, and live birth rates after ICSI-AOA were compared to previous ICSI cycles. In addition, the calcium pattern induced by the male patient’s sperm was investigated by mouse oocyte calcium analysis. Furthermore, all 42 couples underwent genetic screening. Female patients were screened for SCMC genes (TLE6, PADI6, NLRP2, NLRP5, NLRP7, and KHDC3L) and male patients were screened for the sperm–oocyte-activating factor PLCZ1. MAIN RESULTS AND THE ROLE OF CHANCE We compared 17 AOA cycles to 44 previous ICSI cycles from the same patient cohort. After AOA, a total fertilization rate of 68.95% (131/190), a blastocyst development rate of 13.74% (18/131), a pregnancy rate of 29.41% (5/17), and a live birth rate of 23.53% (4/17) were achieved, which was not different from the previous ICSI cycles (76.25% (321/421, P-value = 0.06); 9.35% (30/321, P-value = 0.18), 25.00% (11/44, P-value = 0.75), and 15.91% (7/44, P-value = 0.48), respectively). Calcium analysis showed that patient’s sperm induced calcium patterns similar to control sperm samples displaying normal embryo developmental potential. Genetic screening revealed 10 unique heterozygous variants (in NLRP2, NLRP5, NLRP7, TLE6, and PADI6) of uncertain significance (VUS) in 14 females. Variant NLRP5 c.623-12_623-11insTTC (p.?) was identified in two unrelated individuals and variant NLRP2 c.1572T&gt;C (p.Asp524=) was identified in four females. Interestingly, we identified a previously reported homozygous mutation PLCZ1, c.1499C&gt;T (p.Ser500Leu), in a male patient displaying impaired embryonic development, but not showing typical fertilization failure. LIMITATIONS, REASONS FOR CAUTION Our strict inclusion criteria, requiring at least two ICSI cycles with impaired embryo development, reduced cycle-to-cycle variability, while the requirement of a lower blastocyst development not influenced by a poor fertilization excluded couples who otherwise would be selective cases for AOA; however, these criteria limited the sample size of this study. Targeted genetic screening might be too restricted to identify a genetic cause underlying the phenotype of poor embryo development for all patients. Moreover, causality of the identified VUS should be further determined. WIDER IMPLICATIONS OF THE FINDINGS Strong evidence for AOA overcoming impaired embryonic development is still lacking in the literature. Thus far, only one article has reported a beneficial effect of AOA (using calcimycin) compared to previous ICSI cycles in this patient population, whilst two more recent sibling-oocyte control studies (one using calcimycin and the other ionomycin) and our research (using ionomycin) could not corroborate these findings. Although no major abnormalities have been found in children born after AOA, this technique should be reserved for couples with a clear Ca2+-release deficiency. Finally, genetic screening by whole-exome sequencing may reveal novel genes and variants linked to embryo developmental problems and allow the design of more personalized treatment options, such as wild-type complementary RNA or recombinant protein injection. STUDY FUNDING/COMPETING INTEREST(S) This study was supported by the Flemish Fund for Scientific Research (grant FWO.OPR.2015.0032.01 to B.H. and grant no. 1298722N to A.B.). A.C.B., D.B., A.B., V.T., R.P., F.M., I.D.C., L.L., D.S., P.D.S., P.C., and F.V.M. have nothing to disclose. B.H. reports a research grant from the Flemish Fund for Scientific Research and reports being a board member of the Belgian Society for Reproductive Medicine and the Belgian Ethical Committee on embryo research. TRIAL REGISTRATION NUMBER NCT03354013" @default.
• W4327701904 created "2023-03-18" @default.
• W4327701904 creator A5009862399 @default.
• W4327701904 creator A5015831817 @default.
• W4327701904 creator A5023161394 @default.
• W4327701904 creator A5029037934 @default.
• W4327701904 creator A5040643286 @default.
• W4327701904 creator A5041420472 @default.
• W4327701904 creator A5045578157 @default.
• W4327701904 creator A5046348764 @default.
• W4327701904 creator A5052868684 @default.
• W4327701904 creator A5065437445 @default.
• W4327701904 creator A5082235256 @default.
• W4327701904 creator A5084267541 @default.
• W4327701904 creator A5090251557 @default.
• W4327701904 date "2023-03-17" @default.
• W4327701904 modified "2023-09-29" @default.
• W4327701904 title "Assisted oocyte activation does not overcome recurrent embryo developmental problems" @default.
• W4327701904 cites W2006693497 @default.
• W4327701904 cites W2012675810 @default.
• W4327701904 cites W2019817696 @default.
• W4327701904 cites W2023291869 @default.
• W4327701904 cites W2039780593 @default.
• W4327701904 cites W2044573154 @default.
• W4327701904 cites W2047364183 @default.
• W4327701904 cites W2051978340 @default.
• W4327701904 cites W2055512050 @default.
• W4327701904 cites W2057657772 @default.
• W4327701904 cites W2070640442 @default.
• W4327701904 cites W2072465246 @default.
• W4327701904 cites W2093514139 @default.
• W4327701904 cites W2093613850 @default.
• W4327701904 cites W2097939257 @default.
• W4327701904 cites W2098620041 @default.
• W4327701904 cites W2112778436 @default.
• W4327701904 cites W2114210098 @default.
• W4327701904 cites W2124656409 @default.
• W4327701904 cites W2134341806 @default.
• W4327701904 cites W2156058320 @default.
• W4327701904 cites W2156164053 @default.
• W4327701904 cites W2176041179 @default.
• W4327701904 cites W2182606439 @default.
• W4327701904 cites W2279461931 @default.
• W4327701904 cites W2492776710 @default.
• W4327701904 cites W2515900059 @default.
• W4327701904 cites W2518658526 @default.
• W4327701904 cites W2565223955 @default.
• W4327701904 cites W2619554679 @default.
• W4327701904 cites W2698185966 @default.
• W4327701904 cites W2750760157 @default.
• W4327701904 cites W2767514012 @default.
• W4327701904 cites W2784061244 @default.
• W4327701904 cites W2785490505 @default.
• W4327701904 cites W27890539 @default.
• W4327701904 cites W2790654123 @default.
• W4327701904 cites W2795137931 @default.
• W4327701904 cites W2912884349 @default.
• W4327701904 cites W2917279769 @default.
• W4327701904 cites W2921957773 @default.
• W4327701904 cites W2932289576 @default.
• W4327701904 cites W2946382119 @default.
• W4327701904 cites W2949857618 @default.
• W4327701904 cites W2964924071 @default.
• W4327701904 cites W2967738741 @default.
• W4327701904 cites W2997670706 @default.
• W4327701904 cites W3000005356 @default.
• W4327701904 cites W3000358978 @default.
• W4327701904 cites W3014771384 @default.
• W4327701904 cites W3019458629 @default.
• W4327701904 cites W3031226863 @default.
• W4327701904 cites W3039602955 @default.
• W4327701904 cites W3040334134 @default.
• W4327701904 cites W3043383325 @default.
• W4327701904 cites W3043459184 @default.
• W4327701904 cites W3089548437 @default.
• W4327701904 cites W3098444464 @default.
• W4327701904 cites W3107120073 @default.
• W4327701904 cites W3156322183 @default.
• W4327701904 cites W3191271437 @default.
• W4327701904 cites W3199420652 @default.
• W4327701904 cites W3212354748 @default.
• W4327701904 cites W4206903737 @default.
• W4327701904 cites W4206933982 @default.
• W4327701904 cites W4225368801 @default.
• W4327701904 cites W4280610162 @default.
• W4327701904 cites W4293051145 @default.
• W4327701904 cites W4295136875 @default.
• W4327701904 doi "https://doi.org/10.1093/humrep/dead051" @default.
• W4327701904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36931261" @default.
• W4327701904 hasPublicationYear "2023" @default.
• W4327701904 type Work @default.
• W4327701904 citedByCount "1" @default.
• W4327701904 countsByYear W43277019042023 @default.
• W4327701904 crossrefType "journal-article" @default.
• W4327701904 hasAuthorship W4327701904A5009862399 @default.
• W4327701904 hasAuthorship W4327701904A5015831817 @default.
• W4327701904 hasAuthorship W4327701904A5023161394 @default.
• W4327701904 hasAuthorship W4327701904A5029037934 @default.

• next